Literature DB >> 10077612

Different TBX5 interactions in heart and limb defined by Holt-Oram syndrome mutations.

C T Basson1, T Huang, R C Lin, D R Bachinsky, S Weremowicz, A Vaglio, R Bruzzone, R Quadrelli, M Lerone, G Romeo, M Silengo, A Pereira, J Krieger, S F Mesquita, M Kamisago, C C Morton, M E Pierpont, C W Müller, J G Seidman, C E Seidman.   

Abstract

To better understand the role of TBX5, a T-box containing transcription factor in forelimb and heart development, we have studied the clinical features of Holt-Oram syndrome caused by 10 different TBX5 mutations. Defects predicted to create null alleles caused substantial abnormalities both in limb and heart. In contrast, missense mutations produced distinct phenotypes: Gly80Arg caused significant cardiac malformations but only minor skeletal abnormalities; and Arg237Gln and Arg237Trp caused extensive upper limb malformations but less significant cardiac abnormalities. Amino acids altered by missense mutations were located on the three-dimensional structure of a related T-box transcription factor, Xbra, bound to DNA. Residue 80 is highly conserved within T-box sequences that interact with the major groove of target DNA; residue 237 is located in the T-box domain that selectively binds to the minor groove of DNA. These structural data, taken together with the predominant cardiac or skeletal phenotype produced by each missense mutation, suggest that organ-specific gene activation by TBX5 is predicated on biophysical interactions with different target DNA sequences.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10077612      PMCID: PMC15870          DOI: 10.1073/pnas.96.6.2919

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  Familial heart disease with skeletal malformations.

Authors:  M HOLT; S ORAM
Journal:  Br Heart J       Date:  1960-04

2.  The Holt-Oram syndrome.

Authors:  J A Hurst; C M Hall; M Baraitser
Journal:  J Med Genet       Date:  1991-06       Impact factor: 6.318

Review 3.  [Holt-Oram syndrome].

Authors:  C Elek; M Vitéz; E Czeizel
Journal:  Orv Hetil       Date:  1991-01-13       Impact factor: 0.540

4.  Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS).

Authors:  C R Newton; A Graham; L E Heptinstall; S J Powell; C Summers; N Kalsheker; J C Smith; A F Markham
Journal:  Nucleic Acids Res       Date:  1989-04-11       Impact factor: 16.971

Review 5.  [Holt-Oram syndrome].

Authors:  F Kullmann; T Grimm
Journal:  Dtsch Med Wochenschr       Date:  1993-10-08       Impact factor: 0.628

6.  Holt-Oram syndrome: clinical and genetic study of a large family.

Authors:  J C Gall; A M Stern; M M Cohen; M S Adams; R T Davidson
Journal:  Am J Hum Genet       Date:  1966-03       Impact factor: 11.025

7.  Holt-Oram syndrome.

Authors:  A T Smith; G H Sack; G J Taylor
Journal:  J Pediatr       Date:  1979-10       Impact factor: 4.406

8.  The upper limb-cardiovascular syndrome, (Holt-Oram syndrome).

Authors:  R M Letts; A E Chudley; G Cumming; M H Shokier
Journal:  Clin Orthop Relat Res       Date:  1976-05       Impact factor: 4.176

9.  The clinical and genetic spectrum of the Holt-Oram syndrome (heart-hand syndrome)

Authors:  C T Basson; G S Cowley; S D Solomon; B Weissman; A K Poznanski; T A Traill; J G Seidman; C E Seidman
Journal:  N Engl J Med       Date:  1994-03-31       Impact factor: 91.245

10.  The Brachyury gene encodes a novel DNA binding protein.

Authors:  A Kispert; B G Herrmann
Journal:  EMBO J       Date:  1993-08       Impact factor: 11.598

View more
  92 in total

1.  Single allele mutations at the heart of congenital disease.

Authors:  N Rosenthal; R P Harvey
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

2.  Heart or hand? Unmasking the basis for specific Holt-Oram phenotypes.

Authors:  M D Schneider; R J Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

3.  Novel TFAP2B mutations that cause Char syndrome provide a genotype-phenotype correlation.

Authors:  F Zhao; C G Weismann; M Satoda; M E Pierpont; E Sweeney; E M Thompson; B D Gelb
Journal:  Am J Hum Genet       Date:  2001-08-14       Impact factor: 11.025

4.  The spectrum of mutations in TBX3: Genotype/Phenotype relationship in ulnar-mammary syndrome.

Authors:  M Bamshad; T Le; W S Watkins; M E Dixon; B E Kramer; A D Roeder; J C Carey; S Root; A Schinzel; L Van Maldergem; R J Gardner; R C Lin; C E Seidman; J G Seidman; R Wallerstein; E Moran; R Sutphen; C E Campbell; L B Jorde
Journal:  Am J Hum Genet       Date:  1999-06       Impact factor: 11.025

5.  Why study human limb malformations?

Authors:  Andrew O M Wilkie
Journal:  J Anat       Date:  2003-01       Impact factor: 2.610

Review 6.  Genetic disorders of the skeleton: a developmental approach.

Authors:  Uwe Kornak; Stefan Mundlos
Journal:  Am J Hum Genet       Date:  2003-07-31       Impact factor: 11.025

7.  Functional analysis of TBX5 missense mutations associated with Holt-Oram syndrome.

Authors:  Chun Fan; Mugen Liu; Qing Wang
Journal:  J Biol Chem       Date:  2002-12-23       Impact factor: 5.157

Review 8.  Epigenetic mechanisms in cardiac development and disease.

Authors:  Marcus Vallaster; Caroline Dacwag Vallaster; Sean M Wu
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2012-01       Impact factor: 3.848

9.  Hox5 interacts with Plzf to restrict Shh expression in the developing forelimb.

Authors:  Ben Xu; Steven M Hrycaj; Daniel C McIntyre; Nicholas C Baker; Jun K Takeuchi; Lucie Jeannotte; Zachary B Gaber; Bennett G Novitch; Deneen M Wellik
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

10.  Mutations in the EGF-CFC gene cryptic are an infrequent cause of congenital heart disease.

Authors:  Cemil Ozcelik; Nana Bit-Avragim; Anna Panek; Ursula Gaio; Christian Geier; Peter E Lange; Rainer Dietz; Maximilian G Posch; Andreas Perrot; Brigitte Stiller
Journal:  Pediatr Cardiol       Date:  2006-10-27       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.